Search

Your search keyword '"Contino, Silvia"' showing total 12 results
Start Over Author "Contino, Silvia" Search Limiters Full Text
12 results on '"Contino, Silvia"'

1. The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors

Author

Incorvaia, Lorena, Bazan Russo, Tancredi Didier, Gristina, Valerio, Perez, Alessandro, Brando, Chiara, Mujacic, Clarissa, Di Giovanni, Emilia, Bono, Marco, Contino, Silvia, Ferrante Bannera, Carla, Vitale, Maria Concetta, Gottardo, Andrea, Peri, Marta, Galvano, Antonio, Fanale, Daniele, Badalamenti, Giuseppe, Russo, Antonio, and Bazan, Viviana

Published
2024
Full Text
View/download PDF

2. Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family”

Author

Gottardo, Andrea, Gristina, Valerio, Perez, Alessandro, Di Giovanni, Emilia, Contino, Silvia, Barraco, Nadia, Bono, Marco, Iannì, Giuliana, Randazzo, Ugo, Bazan Russo, Tancredi Didier, Iacono, Federica, Incorvaia, Lorena, Badalamenti, Giuseppe, Russo, Antonio, Galvano, Antonio, and Bazan, Viviana

Published
2024
Full Text
View/download PDF

3. Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints

Author

Fanale, Daniele, Corsini, Lidia Rita, Bono, Marco, Randazzo, Ugo, Barraco, Nadia, Brando, Chiara, Cancelliere, Daniela, Contino, Silvia, Giurintano, Ambra, Magrin, Luigi, Pedone, Erika, Perez, Alessandro, Piraino, Paola, Pivetti, Alessia, Giovanni, Emilia Di, Russo, Tancredi Didier Bazan, Prestifilippo, Ornella, Gennusa, Vincenzo, Pantuso, Gianni, Russo, Antonio, and Bazan, Viviana

Published
2024
Full Text
View/download PDF

6. Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: looking for new tumor biological fingerprints

Author

Fanale, Daniele, primary, Corsini, Lidia Rita, additional, Bono, Marco, additional, Randazzo, Ugo, additional, Barraco, Nadia, additional, Brando, Chiara, additional, Cancelliere, Daniela, additional, Contino, Silvia, additional, Giurintano, Ambra, additional, Magrin, Luigi, additional, Pedone, Erika, additional, Perez, Alessandro, additional, Piraino, Paola, additional, Pivetti, Alessia, additional, Giovanni, Emilia Di, additional, Russo, Tancredi Didier Bazan, additional, Prestifilippo, Ornella, additional, Gennusa, Vincenzo, additional, Pantuso, Gianni, additional, Russo, Antonio, additional, and Bazan, Viviana, additional

Published
2023
Full Text
View/download PDF

7. Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

Author

Dimino, Alessandra, primary, Brando, Chiara, additional, Algeri, Laura, additional, Gristina, Valerio, additional, Pedone, Erika, additional, Peri, Marta, additional, Perez, Alessandro, additional, De Luca, Ida, additional, Sciacchitano, Roberta, additional, Magrin, Luigi, additional, Bazan Russo, Tancredi Didier, additional, Bono, Marco, additional, Barraco, Nadia, additional, Contino, Silvia, additional, La Mantia, Maria, additional, Galvano, Antonio, additional, Badalamenti, Giuseppe, additional, Russo, Antonio, additional, Bazan, Viviana, additional, and Incorvaia, Lorena, additional

Published
2022
Full Text
View/download PDF

9. Risk Factors for Anaplastic Thyroid Carcinoma: A Case Series From a Tertiary Referral Center for Thyroid Surgery and Literature Analysis

Author

Graceffa, Giuseppa, primary, Salamone, Giuseppe, additional, Contino, Silvia, additional, Saputo, Federica, additional, Corigliano, Alessandro, additional, Melfa, Giuseppina, additional, Proclamà, Maria Pia, additional, Richiusa, Pierina, additional, Mazzola, Sergio, additional, Tutino, Roberta, additional, Orlando, Giuseppina, additional, and Scerrino, Gregorio, additional

Published
2022
Full Text
View/download PDF

11. Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors.

Author

Dimino, Alessandra, Brando, Chiara, Algeri, Laura, Gristina, Valerio, Pedone, Erika, Peri, Marta, Perez, Alessandro, De Luca, Ida, Sciacchitano, Roberta, Magrin, Luigi, Bazan Russo, Tancredi Didier, Bono, Marco, Barraco, Nadia, Contino, Silvia, La Mantia, Maria, Galvano, Antonio, Badalamenti, Giuseppe, Russo, Antonio, Bazan, Viviana, and Incorvaia, Lorena

Subjects
BIOMARKERS, GENETICS, GENETIC mutation, IMMUNE system, GASTROINTESTINAL tumors, GENE expression, TREATMENT effectiveness, PHENOTYPES, IMMUNOTHERAPY, SARCOMA
Abstract

Simple Summary: The effect of genetic alteration on the prognosis of patients affected by GIST has been extensively demonstrated. Unfortunately, not all GISTs could benefit from targeted therapies, underlining the need to deeply understand other predictive mechanisms. The link between immune checkpoints (especially PD-L1 expression), the tumor microenvironment, and the clinical behavior of GIST with different driver mutations is under investigation and represents an intriguing research field that could lead to improved prognostication in GIST. Gastrointestinal Stromal Tumors (GISTs) represent a paradigmatic model of oncogene addiction. Despite the well-known impact of the mutational status on clinical outcomes, we need to expand our knowledge to other factors that influence behavior heterogeneity in GIST patients. A growing body of studies has revealed that the tumor microenvironment (TME), mostly populated by tumor-associated macrophages (TAMs) and lymphocytes (TILs), and stromal differentiation (SD) have a significant impact on prognosis and response to treatment. Interestingly, even though the current knowledge of the role of immune response in this setting is still limited, recent pre-clinical and clinical data have highlighted the relevance of the TME in GISTs, with possible implications for clinical practice in the near future. Moreover, the expression of immune checkpoints, such as PD-L1, PD-1, and CTLA-4, and their relationship to the clinical phenotype in GIST are emerging as potential prognostic biomarkers. Looking forward, these variables related to the underlying tumoral microenvironment in GIST, though limited to still-ongoing trials, might lead to the potential use of immunotherapy, alone or in combination with targeted therapy, in advanced TKI-refractory GISTs. This review aims to deepen understanding of the potential link between mutational status and the immune microenvironment in GIST. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

Author

Alessandra Dimino, Chiara Brando, Laura Algeri, Valerio Gristina, Erika Pedone, Marta Peri, Alessandro Perez, Ida De Luca, Roberta Sciacchitano, Luigi Magrin, Tancredi Didier Bazan Russo, Marco Bono, Nadia Barraco, Silvia Contino, Maria La Mantia, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia, Dimino, Alessandra, Brando, Chiara, Algeri, Laura, Gristina, Valerio, Pedone, Erika, Peri, Marta, Perez, Alessandro, De Luca, Ida, Sciacchitano, Roberta, Magrin, Luigi, Bazan Russo, Tancredi Didier, Bono, Marco, Barraco, Nadia, Contino, Silvia, La Mantia, Maria, Galvano, Antonio, Badalamenti, Giuseppe, Russo, Antonio, Bazan, Viviana, and Incorvaia, Lorena

Subjects
Cancer Research, immune system, Oncology, target therapy, tumor microenvironment, immunotherapy, immune checkpoints, sarcomas, GIST
Abstract

Gastrointestinal Stromal Tumors (GISTs) represent a paradigmatic model of oncogene addiction. Despite the well-known impact of the mutational status on clinical outcomes, we need to expand our knowledge to other factors that influence behavior heterogeneity in GIST patients. A growing body of studies has revealed that the tumor microenvironment (TME), mostly populated by tumor-associated macrophages (TAMs) and lymphocytes (TILs), and stromal differentiation (SD) have a significant impact on prognosis and response to treatment. Interestingly, even though the current knowledge of the role of immune response in this setting is still limited, recent pre-clinical and clinical data have highlighted the relevance of the TME in GISTs, with possible implications for clinical practice in the near future. Moreover, the expression of immune checkpoints, such as PD-L1, PD-1, and CTLA-4, and their relationship to the clinical phenotype in GIST are emerging as potential prognostic biomarkers. Looking forward, these variables related to the underlying tumoral microenvironment in GIST, though limited to still-ongoing trials, might lead to the potential use of immunotherapy, alone or in combination with targeted therapy, in advanced TKI-refractory GISTs. This review aims to deepen understanding of the potential link between mutational status and the immune microenvironment in GIST.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results